Leerink Partnrs issued their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will ...

SAN DIEGO—Ingmar Bruns, the Chief Medical (TASE:PMCN) Officer of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently purchased 20,000 shares of the company's common stock. The shares were ...

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small ...

Officer of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently purchased 20,000 shares of the company's common stock. The shares were acquired at a price of $2.2828 each, totaling $45,656.

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small ...